Kling Bio, a biotech company developing antibody-based drugs for cancer and infectious diseases, has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using its proprietary B cell immortalization and screening platform, Kling-Select. The partnership focuses on identifying monoclonal antibodies with potent neutralizing activity against a clinically relevant human viral pathogen.
Kling-Select Platform Technology
Kling-Select is a proprietary, clinically and commercially validated B cell immortalization platform that has played a pivotal role in the discovery of potent neutralizing antibodies. By leveraging patient-derived B cells, Kling-Select enables rapid identification of novel antibodies and conserved viral epitopes, significantly enhancing vaccine and therapeutic design.
The platform utilizes a function-first screening workflow that uncovers rare and highly effective immune targets, accelerating the development of next-generation prophylactics and treatments. This approach provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes.
Proven Track Record
The platform's proven success includes validated antibody candidates against RSV, COVID-19, and influenza, underscoring its broad utility and scientific impact. These achievements demonstrate the platform's ability to address multiple viral pathogens and support the development of diverse therapeutic applications.
Collaboration Objectives
The objective of the collaboration is to identify and characterize monoclonal antibodies with potent neutralizing activity against a clinically relevant human viral pathogen. Insights gained from this joint discovery effort may enable the development of next-generation antiviral therapeutics and inform the design of more efficacious vaccine candidates.
"This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies," commented Michael Koslowski, MD, Chief Executive Officer of Kling Bio. "Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi's leadership in vaccine development to advance next-generation therapeutics and vaccines."
Strategic Partnership Impact
The collaboration underscores Kling Bio's commitment to transforming disease prevention and treatment through advanced antibody discovery technologies. By combining Kling Bio's expertise in antibody discovery with Sanofi's leadership in vaccine development, the partnership aims to advance both therapeutic and preventive approaches to viral diseases.
The partnership represents a significant step forward in leveraging human-derived immune responses to develop more effective treatments and vaccines against viral pathogens, potentially addressing critical unmet medical needs in infectious disease management.
